CD8A and neoplasm: Moreover, the recent study from liver cancer patients treated with ICB demonstrated that low tumour transcriptomic diversity and higher cytolytic activity of CD8+ T cells, consistent with our tumours with low immune-ITH, predicts clinical response to immunotherapy6.